Core Insights - The report highlights a significant discrepancy between patient and physician satisfaction regarding treatment outcomes for myasthenia gravis, with over 74.2% of patients expressing satisfaction while 43.2% still face issues with symptom control or side effects [1][2] Group 1: Treatment Satisfaction - The report indicates that patients exhibit a "discrepancy" in treatment satisfaction, with a majority satisfied but still experiencing unresolved symptoms [1] - Physicians generally report higher satisfaction levels compared to patients, suggesting a gap in understanding patient experiences and expectations [1][2] Group 2: Treatment Goals - A notable 39.4% of patients prioritize reducing treatment side effects over symptom control and relapse prevention, indicating a shift in treatment focus [2] - The concept of "dual targets" in treatment—efficacy and safety—has been established as a common goal among healthcare professionals [2] Group 3: Patient Monitoring - The ADL assessment tool is emphasized as crucial for monitoring disease progression and treatment effectiveness, yet less than 10% of patients utilize it weekly [3] - Regular self-assessment using the ADL scale can help patients and physicians better understand symptom control and side effects [3]